Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19107


Purpose:

This is a randomized, placebo controlled study. The first subject is expected to be enrolled in July 2014, and the last subject is expected to complete the study by July 2015. Each subject will be provided with the PRN Joint Comfort Formula, placebo or PRN Flex Omega Benefits® combination depending on randomization (1:1:1 at each site) during the course of the study. Instructions and frequency of use will be determined by the labelling.


Criteria:

Inclusion Criteria: - Age ≥18 and ≤ 90 at the time of informed consent. - Subjects with symptomatic moderate arthritis of the knee defined as per - Kellgren-Lawrence grade II or III (Appendix B). Subjects with bilateral arthritis of the knee will also be recruited, but only one knee will be enrolled into the study. - Ability to walk 50 feet unassisted. - Lequesne's Functional Index score greater than 7 points Exclusion Criteria: - Subjects with systemic inflammatory conditions such as inflammatory bowel disease, psoriasis, eczema, and others - Subjects with seropositive or sero-negative inflammatory arthritis of the knee such as rheumatoid arthritis or ankylosing spondylitis. - Subjects taking hormone replacement therapy - Intra-articular corticosteroid injections 3 weeks prior to enrollment. - Hypersensitivity to fish oil. - Hypersensitivity to non-steroidal anti-inflammatory drugs, abnormal liver of kidney function tests, history of peptic ulceration and upper gastrointestinal hemorrhage, congestive heart failure, Hypertension (BP>140/90), cancer and hyperkalemia. - Major abnormal findings on complete blood count, history of coagulopathies, hematological or neurological disorders. - High alcohol intake (>2 standard drinks per day). Pregnant, breastfeeding or planning to become pregnant during the study - Subjects awaiting surgery on the affected knee within three months. - Consumption of any other vitamins/supplements will be allowed, provided the dose is not increased, and same brand is continued with. Also, the regimen should not contain the same active compounds tested in the PRN Joint health formula product. - Vitamins/supplements cannot be introduced during a subject's participation in the study.


NCT ID:

NCT02333084


Primary Contact:

Principal Investigator
Javad Parvizi, MD
Rothman Institute


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19107
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 24, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.